title: Pathologic 'fused gland' as a prognostic factor for prostate cancer.
abstract: We examined the significance of a pathologic 'fused gland' according to the WHO-Mostofi classification for predicting prognosis in hormonally treated prostate cancer. Of 284 newly diagnosed patients receiving hormone therapy, 60 patients had specimens with no 'medullary' or 'column-cord' elements. Twenty-five of these had a 'fused gland', while 35 did not. Survival of these patients was analyzed. Cause-specific survival of the patients with no medullary or column-cord elements showed a significantly better prognosis compared to others. Furthermore, the patients whose specimens contained a 'fused gland' component had significantly poorer survival than those without that component, suggesting that the 'fused gland' component is a poor prognostic factor for survival in patients with hormonally treated prostate cancer.
authors.affiliation: Department of Urology, Yohokama City University School of Medicine, Yokohama, Japan. rn1009@yellow.med.yokohama-cu.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: I
authors.initials: I
authors.lastname: Kondoh
authors.forename: M
authors.initials: M
authors.lastname: Harada
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: H
authors.initials: H
authors.lastname: Uemura
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal